Respiratory syncytial virus

Lore & Background

Respiratory syncytial virus (RSV) is a negative-sense, single-stranded RNA virus. Its name derives from the large, multinucleated cells called syncytia that form when infected cells fuse. The virus primarily infects the epithelial cells of the upper and lower airways after entering through the eyes or nasal passages, causing inflammation, cell damage, and airway obstruction. RSV is a common cause of respiratory hospitalization in infants, and while reinfection occurs frequently throughout life, it is often less severe. Infection rates are typically higher during cold winter months. In infants, RSV commonly causes bronchiolitis, while in adults it typically presents as a common cold. Older individuals and those with compromised immune systems, such as from cardiopulmonary disease, are at risk for more serious illnesses like pneumonia. The virus can cause outbreaks in both community and hospital settings. Detection and diagnosis are achieved through antigen testing, molecular testing, and viral culture. Prevention measures include hand-washing and avoiding close contact with infected individuals. The virus is carried in respiratory aerosols, and fine and ultrafine aerosols produced during normal breathing, talking, and coughing suggest airborne precautions may be needed for reliable protection. The first RSV vaccines were approved by the US Food and Drug Administration in May 2023. Prophylactic monoclonal antibody treatments, palivizumab and nirsevimab, can prevent infection in high-risk infants. Treatment for severe illness is primarily supportive, including oxygen therapy, CPAP, or nasal high flow oxygen, and in cases of respiratory failure, intubation and mechanical ventilation. Ribavirin is an antiviral medication licensed for RSV treatment in children.

Reader's Guide

Respiratory syncytial virus is a significant global pathogen, particularly affecting infants, older adults, and immunocompromised individuals. Nearly all children in the United States experience at least one RSV infection before two years of age, and it is responsible for about 70% of bronchiolitis cases. In adults, reinfection is common but usually mild, though the elderly and those with underlying conditions face higher risks of pneumonia and death. The virus can cause outbreaks in both community and hospital settings. Prophylactic monoclonal antibodies (palivizumab or nirsevimab) can prevent infection in high-risk infants. Treatment for severe illness is primarily supportive, including oxygen therapy and mechanical ventilation if needed. The virus's transmission via respiratory aerosols suggests airborne precautions may be necessary for reliable protection.

Did You Know?

• The virus's name comes from the large, multinucleated cells (syncytia) that form when infected cells fuse.
• Bovine RSV shares about 80% of its genome with human RSV and causes similar disease in calves, serving as an important animal model.

Droplet-Borne Spread as RSV's Primary Vector

RSV is classified among the respiratory viruses that travel primarily through droplet transmission. This means the virus is expelled when an infected person coughs, sneezes, or even talks, producing particles larger than five micrometers. Unlike truly airborne pathogens such as tuberculosis or measles, RSV droplets are too large to linger in the air for extended periods. They fall to the ground or onto nearby surfaces within a short distance, making close proximity the key risk factor. The virus can land directly on the eyes, nose, or mouth of a susceptible person, or it can settle on a surface and later be transferred when someone touches their face with contaminated hands. This short-range, contact-adjacent behavior is what distinguishes RSV from the more elusive airborne threats and shapes how healthcare settings and households approach its containment.

Prevention Strategies Tailored to Droplet Physics

Because RSV travels in relatively large droplets rather than as tiny aerosol nuclei, the infection-control strategies that apply differ markedly from those used for measles or tuberculosis. Negative-pressure rooms and dedicated ventilation systems, while critical for airborne pathogens, are not the primary defense against RSV. Instead, the emphasis falls on reducing the emission of droplets at the source—wearing a surgical mask over the nose and mouth of an infected person is cited as a practical way to cut down the volume of respiratory particles released during coughing, sneezing, or conversation. Equally important is breaking the indirect chain: frequent hand-washing and disinfection of shared surfaces interrupt the fomite pathway by which the virus reaches the eyes, nose, or mouth of a new host. In settings where children congregate, these simple mechanical barriers become the backbone of outbreak prevention, since the virus cannot sustain itself in the air long enough to require the more elaborate engineering controls reserved for true airborne diseases.

Pediatric Vulnerability and the Challenge of Community Transmission

RSV occupies a particularly troubling position in pediatric public health, and the routes by which it spreads compound that vulnerability. In addition to the familiar droplet pathway, the fecal-oral route—transmission through unwashed hands, contaminated food, or poor water and sanitation—carries outsized weight in young children and in developing regions where hygiene infrastructure is limited. This dual exposure means that even in households with careful respiratory etiquette, a toddler can pick up the virus from a contaminated toy, a shared cup, or a caregiver's hands after handling a diaper. When the source of infection cannot be traced to a specific contact or travel link, the situation is classified as community transmission, a label that signals the virus is circulating invisibly within a population. For epidemiologists, the difficulty of mapping each chain of spread in dense, mobile communities makes RSV one of the hardest pediatric pathogens to contain, especially where clean water access and sanitation remain inconsistent.

The 2024 WHO Terminology Overhaul and Its Policy Gap

The new framework, aligned with particle physics, replaces older, sometimes overlapping language with four precise categories: airborne transmission, inhalation, direct deposition, and contact. Under this scheme, RSV's characteristic short-range droplet spread and surface-mediated transfer would be captured more accurately than under the older labels that blurred the distinction between particles that remain suspended and those that simply fall. However, as of the time of reporting, these refined definitions have not yet been woven into actionable policy. Infection-control guidelines, the pandemic accords, and the updated International Health Regulations still rely on the previous terminology, leaving a gap between the scientific precision now available and the operational language that hospitals, public-health agencies, and international bodies actually use to protect populations from RSV and its respiratory peers.